Milestone Pharmaceuticals Inc. (NASDAQ:MIST) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 19,200 shares, a decline of 11.9% from the September 30th total of 21,800 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average trading volume of 7,500 shares, the days-to-cover ratio is presently 2.6 days.
Several research analysts have recently commented on MIST shares. Cowen reiterated a “buy” rating and set a $32.00 target price on shares of Milestone Pharmaceuticals in a research note on Thursday. ValuEngine upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, Zacks Investment Research downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Milestone Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $30.10.
MIST traded up $0.63 during trading on Friday, hitting $17.66. The stock had a trading volume of 5,100 shares, compared to its average volume of 3,505. Milestone Pharmaceuticals has a one year low of $15.09 and a one year high of $27.95. The stock has a 50 day simple moving average of $18.97.
Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, November 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). On average, sell-side analysts predict that Milestone Pharmaceuticals will post -3.32 EPS for the current year.
In other Milestone Pharmaceuticals news, major shareholder Stonepine Capital, L.P. bought 100,000 shares of Milestone Pharmaceuticals stock in a transaction dated Friday, October 11th. The stock was bought at an average cost of $0.63 per share, for a total transaction of $63,000.00. Also, major shareholder Rtw Investments, Lp bought 8,150 shares of Milestone Pharmaceuticals stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average price of $17.79 per share, with a total value of $144,988.50. Insiders have bought a total of 113,637 shares of company stock valued at $311,967 over the last quarter.
A number of institutional investors and hedge funds have recently modified their holdings of MIST. Tower Research Capital LLC TRC acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $51,000. Landscape Capital Management L.L.C. acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $459,000. Pentwater Capital Management LP acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $679,000. VHCP Management II LLC acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $4,033,000. Finally, Zimmer Partners LP acquired a new position in Milestone Pharmaceuticals in the 2nd quarter worth about $4,344,000. 53.25% of the stock is owned by institutional investors and hedge funds.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Read More: Is the QQQ ETF safe?
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.